Novavax, Inc. (NVAX)
| Market Cap | 13.54B |
| Revenue (ttm) | 919.45M |
| Net Income (ttm) | -615.11M |
| Shares Out | 73.04M |
| EPS (ttm) | -9.51 |
| PE Ratio | n/a |
| Forward PE | 28.41 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | August 3 |
| Last Price | $184.77 |
| Previous Close | $182.72 |
| Change ($) | 2.05 |
| Change (%) | 1.12% |
| Day's Open | 183.04 |
| Day's Range | 178.95 - 186.35 |
| Day's Volume | 1,404,200 |
| 52-Week Range | 76.59 - 331.68 |
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Novavax stock has declined by almost 12% over the last week (five trading days), compared to the S&P 500 which has remained roughly flat over the same period. The stock is also down by almost 16% over t...
Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress. The post Covid-19 Vaccine Dose Delay Spells Even More Trouble for...
The latecomer could still carve out a spot for itself among the big vaccine makers.
Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days. The post Don't Buy Novavax Until Its Covid-19 Vaccine Wins FDA Appro...
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After moving at less than warp speed, can this vaccine company catch up to the global opportunity?
You have the power to turn a negative event into something positive.
They will give us clues about when to expect billions in revenue.
There could be delays with the company supplying COVID-19 vaccine doses to Australia.
While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture. The post Novavax Stock May Not Get the Delta Varient Bump Investors Nee...
The answer is in the first two letters of the vaccine maker's name.
As the Dogecoin bubble bursts, these high-growth stocks are blossoming.
Despite sizzling year-to-date gains, these stocks are surprisingly inexpensive.
Yes, but it often doesn't have much to do with revenue.
Concerns about the delta variant are rising.
Novavax is worth roughly 100% more. NVAX stock is worth $419 given its high efficacy, cheap price, easy storage and cheap valuation compared to Moderna.
Novavax stock has rallied by almost 12% over the last week (five trading days), compared to the S&P 500 which was down by almost 3% over the same period. The stock is also up by a solid 85% year-to-date.
Novavax (NVAX) closed at $207.19 in the latest trading session, marking a -1.58% move from the prior day.
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...
Stocks begin week with the market selling off; why? The post This Is Why Stocks Are Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Novavax, Inc. (NASDAQ: NVAX) shares rallied higher Monday after renewed COVID-19 concerns. The new Delta variant has been spreading and is a major concern with it recently becoming the dominant strain o...
NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms. The post Plenty of Upside Potential Looms Ahead of Novavax Stock's Bumpy Road appeared...
Catalysts for the shares are right around the corner.
In the latest trading session, Novavax (NVAX) closed at $179.14, marking a +0.75% move from the previous day.
Investors were increasingly confident that the company's COVID-19 vaccine would be successful.
Triple-digit revenue growth awaits this popular trio of companies next year.
Novavax (NVAX) closed at $188.59 in the latest trading session, marking a -0.55% move from the prior day.
Investors appear to be worried about the impact of the delta variant.
COVID-19 concerns are driving the vaccine stocks higher.
The company finally got some good news about its vaccine production schedule.
Stock markets moved slightly higher despite general worries.
Novavax, Inc. (NASDAQ:NVAX) shares tumbled lower Wednesday after retail traders were able to push the stock lower. Vaccine stocks were very volatile today, and many are trading lower amid possible profi...
Today's significant selloff appears to be tied at least in part to some large stock sales made by the company's CEO earlier this month. The post NVAX Stock: One Big Reason Novavax Is Struggling Today ap...
Novavax published results of its U.S. phase 3 trials for its Covid-19 vaccine in mid-June, noting that the shot was over 90% effective overall and 100% effective against moderate and severe disease, rou...
Novavax should take off as its successful Covid-19 vaccine spreads. NVAX stock is worth at least 50% more, given a mixture of analysts' estimates and comp analysis.
NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.
GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report ...
On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was...
In the latest trading session, Novavax (NVAX) closed at $217.22, marking a +0.68% move from the previous day.
It involves producing a vaccine in great volume.
Value stocks have a knack for outperforming during the early stages of an economic recovery.
There's a case to be made that it is.
Let's use recent efficacy data as a starting point.
Wall Street expects gains in the coming year.
Major catalysts are on the horizon.
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate... [Read more...]
| Industry Biotechnology | IPO Date Dec 5, 1995 |
| CEO Stanley Erck | Employees 792 |
| Stock Exchange NASDAQ | Ticker Symbol NVAX |
Financial Performance
In 2020, Novavax's revenue was $475.60 million, an increase of 2,448.48% compared to the previous year's $18.66 million. Losses were -$418.26 million, 215.2% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for Novavax stock is "Buy." The 12-month stock price forecast is 271.75, which is an increase of 47.07% from the latest price.